Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new analysis from the DESTINY-Breast09 trial shows that T-DXd plus pertuzumab dramatically outperforms standard chemo-based therapy in HER2-positive breast cancer patients with brain metastases. The combo nearly tripled median systemic progression-free survival (36.5 vs. 11.1 months) and showed strong intracranial response rates. These findings reinforce T-DXd's growing role as a first-line standard of care, even for patients with CNS involvement.
An exploratory analysis of the phase 3 DESTINY-Breast09 trial, presented at the 2026 ESMO Congress, reveals that T-DXd plus pertuzumab delivers remarkable benefits for patients with HER2-positive advanced or metastatic breast cancer who have brain metastases at baseline. Compared to the standard taxane, trastuzumab, and pertuzumab (THP) regimen, the T-DXd combo more than tripled median systemic progression-free survival and showed superior intracranial control — a notoriously difficult-to-treat complication.
The results build on the FDA's December 2025 approval of T-DXd plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer, and now extend that evidence to a high-risk subgroup often underrepresented in clinical trials.
By the Numbers:
Why it matters: Brain metastases in HER2-positive breast cancer represent a major clinical challenge with limited treatment options. These data suggest T-DXd plus pertuzumab can meaningfully control both systemic and intracranial disease, potentially reshaping first-line treatment decisions for this vulnerable patient population.
